The trial of nearly 2,750 people also saw weight loss and better blood sugar with the daily pill, though the report flags a catch worth reading about.
Recap by typeshit. Full story at Welltica+ on MSN.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Researchers used AI to identify fungal peptides that taste salty or boost saltiness, aimed at cutting sodium in food. A food science find rather than a drug story.
The 1,200-person trial starts next year with MIT and Pitt researchers, funded by a $13 million Arnold Ventures grant, and will also track housing and jobs.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
24:34
An animated explainer walking through what semaglutide does in the body, from appetite signals in the brain to digestion and blood sugar control.
Dr. Nadolsky, an obesity medicine doctor, gives his take on a recent GLP-1 warning in a short clip. Tap through to see which warning he means.
Loading…